New liquid chromatography coupled with mass spectrometry method for ciprofloxacin monitoring in human plasma

Studia Universitatis Babes-Bolyai Chemia

Volumn , Issue 3, 2010, Pages 65-74

  Imre, Silvia ^a   Vancea, Szende ^a   Dogaru, Grigore ^a   Cǎldǎraru, Carmen ^a   Vari, Camil Eugen ^a   Dogaru, Maria Titica ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Ciprofloxacin; Human plasma; LC MS; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

EID: 79251633768     PISSN: 12247154     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Physician's Desk Reference, Medical Economics Company, Inc at Montvale, NJ, USA, 2001, sec. 5, 848.
2. Z. Spektor, M.C. Jasek, D. Jasheway, D.C. Dahlin, D.J. Kay, R. Mitchell, R. Faulkner, G.M. Wall, Int. J. Pediatr. Otorhinolaryngol., 2008, 72, 97.
3. Q. Chen, E.C. Tung, S.L. Ciccotto, J.R. Strauss, R. Ortiga, K.A. Ramsay, W. Tang, Xenobiotica, 2008, 38, 76.
4. C. Bugge, M. Sullivan, M. Tan, AAPS J., 2005, http://www.aapsj.org/abstracts/AM_2005/AAPS2005-001539.pdf
5. X. Peng, J. Lee, A. Pinnawala, G. de Boer, S. Ostonal, E. Chung, G. van der Gugten, AAPS J., 2008, http://www.aapsj.org/abstracts/AM_2008/AAPS2008-003100.PDF
6. S. Imre, M.T. Dogaru, C.E. Vari, T. Muntean, L. Kelemen, J. Pharm. Biomed. Anal., 2003, 33, 125.
7. The European Agency for the Evaluation of Medicinal Products, Note for Guidance on the Investigation of Bioavailability and Bioequivalence, CPMP/EWP/QWP/1401/98, July 2001, London, UK, http://www.emea.europa.eu/pdfs/human/qwp/140198enfin.pdf
8. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Bioavailability and Bioequivalence studies for orally administered drug products - general considerations, March 2003, Rockville, USA, http://www.fda.gov/cder/guidance/5356fnl.pdf
9. U.S. Department of Health and Human Services, Food and Drug Administration, Guidance for Industry - Bioanalytical Method Validation, May 2001, http://www.fda.gov/cder/guidance/4252fnl.pdf